MedPath
HSA Product

AMINOVEN SOLUTION FOR INFUSION 15%

Product approved by Health Sciences Authority (SG)

Basic Information

AMINOVEN SOLUTION FOR INFUSION 15%

INFUSION, SOLUTION

Regulatory Information

SIN16337P

September 30, 2021

Prescription Only

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

XB05BA01

Company Information

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Active Ingredients

L-Valine

Strength: 5.5g/L

L-Serine

Strength: 9.6g/L

L-Tryptophan

Strength: 1.6g/L

Glycine

Strength: 18.5g/L

Taurine

Strength: 2g/L

L-Phenylalanine

Strength: 5.5g/L

L-Methionine

Strength: 3.8g/L

L-Tyrosine

Strength: 0.4g/L

L-Isoleucine

Strength: 5.2g/L

L-Threonine

Strength: 8.6g/L

L-Histidine

Strength: 7.3g/L

L-Alanine

Strength: 25g/L

L-Leucine

Strength: 8.9g/L

L-Arginine

Strength: 20g/L

L-Proline

Strength: 17g/L

Detailed Information

Contraindications

**Contraindications** As for all amino acid solutions, the administration of **Aminoven 15%** is contraindicated in the following conditions: Disturbances of amino acid metabolism, metabolic acidosis, renal insufficiency without haemodialysis or haemofiltration treatment, advanced liver insufficiency, fluid overload, shock, hypoxia, decompensated heart failure. The administration of **Aminoven 15%** is contraindicated in children. For parenteral nutrition of infants and children paediatric amino acid preparations should be used, which are formulated to meet the different metabolic needs of children. No clinical studies have been conducted with **Aminoven 15%** solution in newborns, infants or children.

Indication Information

**Therapeutic indications** For supply of amino acids, as part of a parenteral nutrition regimen. **Aminoven 15%** is mainly indicated if during parenteral nutrition therapy the fluid volume has to be restricted. Amino acid solutions should be administered generally in combination with adequate amount of energy supplements.

© Copyright 2025. All Rights Reserved by MedPath